Samuel Urrutia-Argueta

10PUBLICATIONS
67CO-AUTHORS
Regenerative medicine (incl. stem cells)Respiratory diseasesPredictive and prognostic markersGene and molecular therapyMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Aug 19, 2025
Mortality and relapse dynamics in AML after three years of complete remission.

Samuel Urrutia, Wei-Ying Jen, Koji Sasaki

|Jul 29, 2025
A clinical guide to TP53 mutations in myeloid neoplasms.

Samuel Urrutia, Terrence N Wong, Daniel C Link

|Feb 01, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.

Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li

|Jul 29, 2023
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.

Samuel Urrutia, Kelly S Chien, Ziyi Li

|Mar 10, 2023
Lung Cancer Screening Knowledge in Four Internal Medicine Programs.

Samuel Urrutia Argueta, Nishraj Basnet, Owais Abdul-Kafi

Pageof 2

Frequent Collaborators

4 joint publications

Koji Sasaki

3 joint publications

Kelly S Chien

3 joint publications

Guillermo Montalban-Bravo

2 joint publications

Hagop Kantarjian